Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Has Average Price Target of $98.31 According to Analysts

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have been given a consensus rating of “Moderate Buy” by the fourteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and ten have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $98.31.

Several research firms recently commented on ARWR. Piper Sandler reaffirmed an “overweight” rating and issued a $126.00 price target (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. The Goldman Sachs Group started coverage on Arrowhead Pharmaceuticals in a report on Thursday, September 24th. They issued a “neutral” rating and a $74.00 target price for the company. JPMorgan Chase & Co. raised their target price on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. B. Riley Financial lifted their price target on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Finally, Chardan Capital reissued a “buy” rating and set a $115.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 31st.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ ARWR opened at $64.19 on Monday. The stock has a market cap of $9.04 billion, a PE ratio of -28.53 and a beta of 1.29. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. Arrowhead Pharmaceuticals has a 12-month low of $34.61 and a 12-month high of $95.49. The company has a 50-day moving average of $80.83 and a 200 day moving average of $75.82.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The business had revenue of $75.25 million during the quarter, compared to analysts’ expectations of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The company’s revenue for the quarter was up 171.0% compared to the same quarter last year. During the same period last year, the business earned ($1.26) earnings per share. As a group, sell-side analysts predict that Arrowhead Pharmaceuticals will post -3.62 EPS for the current fiscal year.

Insider Activity

In other news, Director Adeoye Y. Olukotun sold 2,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the completion of the sale, the director owned 31,600 shares of the company’s stock, valued at $2,747,936. This represents a 5.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Michael S. Perry sold 11,600 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the sale, the director owned 111,459 shares of the company’s stock, valued at $9,730,370.70. This represents a 9.43% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. QRG Capital Management Inc. grew its position in Arrowhead Pharmaceuticals by 7.1% in the second quarter. QRG Capital Management Inc. now owns 4,810 shares of the biotechnology company’s stock worth $392,000 after acquiring an additional 317 shares during the period. Integrated Wealth Concepts LLC increased its stake in Arrowhead Pharmaceuticals by 5.2% during the second quarter. Integrated Wealth Concepts LLC now owns 8,297 shares of the biotechnology company’s stock worth $676,000 after acquiring an additional 412 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in Arrowhead Pharmaceuticals in the second quarter valued at $20,859,000. Nykredit A S purchased a new stake in Arrowhead Pharmaceuticals in the second quarter valued at $367,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at $3,533,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.